Nanobiotix (NBTX) to Release Quarterly Earnings on Monday

Key Points

• Nanobiotix (NBTX) is set to post earnings before the market opens on September 22, 2023, with analysts predicting a loss of ($0.2930) per share and revenue of $3.719 million for the quarter.
• The company's stock is experiencing a 6.0% decline and has a current trading price of $11.57, amidst historical lows of $2.76 and highs of $13.20 over the past year.
• Analysts have a consensus rating of "Moderate Buy" for Nanobiotix, with a price target set at $11.00 and a buy rating reaffirmed by HC Wainwright and a $14.00 target from Leerink Partners.

Nanobiotix (NASDAQ:NBTX - Get Free Report) is expected to announce its H1 2025 results before the market opens on Monday, September 22nd. Analysts expect the company to announce earnings of ($0.2930) per share and revenue of $3.7190 million for the quarter. Parties may visit the the company's upcoming H1 2025 earningresults page for the latest details on the call scheduled for Thursday, October 2, 2025 at 11:40 AM ET.

Nanobiotix Trading Down 6.0%

Shares of NASDAQ NBTX traded down $0.74 during trading on Friday, reaching $11.57. 68,520 shares of the stock were exchanged, compared to its average volume of 50,439. Nanobiotix has a twelve month low of $2.76 and a twelve month high of $13.20. The business's 50-day moving average price is $7.97 and its 200 day moving average price is $5.31.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Leerink Partners set a $14.00 target price on Nanobiotix in a research report on Thursday. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research report on Friday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Nanobiotix has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.